Antibody

124개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved124 programs
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

nivolumab (Opdivo, UCPVax + Nivolumab)

Advanced Non-small Cell Lung Cancer · Advanced Non-small Cell Lung Cancer

#AdvancedNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Active
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 3

Uliledlimab (Uliledlimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#TJ
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 2

ZIM (Zimberelimab, Zimberelimab (ZIM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu Cancer Institute & Hosp…Phase 2

QL1706 (apalolimab and toripalimab, apalolimab and toripalimab (QL1706))

NSCLC; NSCLC (Non-small Cell Lung Cancer) · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#NSCLCNon-smallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#monoclonal-antibody#Tongji
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, atezolizumab / tiragolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#B-cellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleCancer Institute and Hospital, …Phase 2

cadonilimab，bevacizumab，docetaxel (cadonilimab，bevacizumab，docetaxel)

Stage IVB Lung Cancer; Non-Squamous · Stage IVB Lung Cancer

#StageIVBLungCancer#Antibody#Phase2#monoclonal-antibody#Non-Squamous+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

cisplatin, vinorlebine, cetuximab (cisplatin, vinorlebine, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatine, etoposide, cetuximab (cisplatine, etoposide, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

cixutumumab (cixutumumab)

Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer

#RecurrentNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#StageIIIBNon-smallCellLungCancer+1
Trials 1Status Active
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine and rituximab (fludarabine and rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine, rituximab, pixantrone (fludarabine, rituximab, pixantrone)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleArrys TherapeuticsPhase 2

pembrolizumab (Keytruda, grapiprant and pembrolizumab)

Non-small Cell Lung Cancer Adenocarcinoma · Non-small Cell Lung Cancer Adenocarcinom

#Non-smallCellLungCancerAdenocarc#Antibody#Phase2#monoclonal-antibody#Arrys
Trials 1Status Discontinued
AntibodyLimited DatastaleEli LillyPhase 2

ixabepilone + cetuximab (ixabepilone + cetuximab)

Triple Negative Locally Advanced Non-resectable Breast Cancer; Metastatic Breast Cancer · Triple Negative Locally Advanced Non-res

#TripleNegativeLocallyAdvancedNon#Antibody#Phase2#monoclonal-antibody#MetastaticBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

RO5072759 (obinutuzumab, obinutuzumab (RO5072759))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active

6 / 7 pages

← PreviousNext →